Pay in 4 interest-free payments of $14.75 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
LY2784544 significantly inhibits STAT5 phosphorylation in JAK2-V617F Ba/F3 xenografts with a Threshold Effective Dose 50 (TED50) of 12
It was licensed to Glaxo in 1990 and approved in the US in 1999
Formula: C18H18N2S
Similarly in the proliferation assay
MGL-3196 - CAS# 920509-32-6 PTO-253 LY2784544 significantly inhibits STAT5 phosphorylationMGL 3196, CAS No. 920509 32 6, also known as Resmetirom, is a potent and highly selective thyroid hormone receptor agonist in clinical trials for the treatment of dyslipidemia. The beneficial effects of thyroid hormone (TH) on lipid levels are primarily due to its action at the thyroid hormone receptor (THR ) in the liver, while adverse effects, including cardiac effects, are mediated by thyroid hormone receptor (THR ). Product information CAS Number:
US$ 524.50
US$ 224.50
US$ 749.50
US$ 1749.50